Power vaccination against cancer boosts the immune system

New hope: Researchers are mobilising the immune system's defence against tumour cells within just two weeks using a two-phase vaccination regimen

29-Apr-2025 - Our body's own defence system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumour cells are easily recognisable by the immune system. In addition, they are constantly changing and camouflaging themselves to evade the defence system. In order to treat ...

New vaccine concept tackles harmful bacteria in the intestine

New approach could potentially mark a turning point in the antibiotics crisis

07-Apr-2025 - The issue of intestinal bacteria is a complex one. On the one hand, we are dependent on the microorganisms because they are the ones that digest the food in our intestine. On the other hand, there are also numerous pathogens present among the bacteria. Some of these pathogens can cause diarrhoea, ...

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

28-Mar-2025 - CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced that the European Patent Office (EPO) has confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to ...

mRNA-based COVID-19 vaccines train the ‘long-term memory’ of the immune system

Findings have far-reaching implications for the development of future vaccination strategie

28-Mar-2025 - Researchers at the University of Cologne and University Hospital Cologne have shown in their study that the novel mRNA-based COVID-19 vaccines not only induce acquired immune responses such as antibody production, but also cause persistent epigenetic changes in innate immune cells. The study ...

Not all myocarditis is the same

28-Feb-2025 - Heart muscle inflammation differs depending on the trigger - be it COVID-19, the mRNA vaccination against COVID-19 or other causes. These findings pave the way for more tailored therapies, report Berlin researchers together with international colleagues in "Nature Cardiovascular Research". The ...

Researchers take step toward creating Salmonella vaccine

10-Feb-2025 - Salmonella might seem like a mild inconvenience to some, but for sensitive groups, it can prove dangerous or deadly. In fact, 26,500 people are hospitalized by the bacterial infection each year in the U.S., and 420 people die, according to the U.S. Centers for Disease Control and Prevention. In ...

ETH Zurich researcher aims to prevent urinary tract infections with a vaccine

Her start-up Baxiva is developing a vaccine that makes bacteria visible to the immune system

03-Feb-2025 - Every second woman and every eighth man suffer from urinary tract infections. These are painful and can recur with serious health consequences. Pioneer Fellow Giorgia Greter has a solution. Giorgia Greter could have been sitting in one of these minimalist, but elegant offices of a venture capital ...

Small antibody offers broad protection against influenza

“It’s rare to find a molecule capable of protecting against so many different influenza viruses”

14-Jan-2025 - Researchers at the University of Gothenburg, Sweden, in collaboration with colleagues in China, have discovered an antibody-like molecule that can protect mice from various influenza viruses. The findings could pave the way for new treatments and the development of broader influenza ...

Researchers develop RSV vaccine with innovative vaccine technology

A one-time vaccination with long-lasting protection would be a real game changer in many respects

09-Jan-2025 - Researchers at the Helmholtz Centre for Infection Research (HZI) have developed a promising new vaccine technology. Their studies to date show that just one dose of vaccine leads to effective and long-lasting immune protection. The basis of this so-called MCMV vaccine vector technology is the ...

Start-up EBViously founded

Innovative vaccine based on virus-like particles

18-Dec-2024 - EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, ...